Deputy Director, Clinical Research Associates
 
 

Paul Wang joined the foundation in 2016 as deputy director of Clinical Research Associates. He is a developmental-behavioral pediatrician with broad experience across academia, industry and the nonprofit/advocacy world. Wang earned a B.A. from Harvard University and an M.D. from the Yale University School of Medicine. He completed his pediatric residency at the University of Michigan, a subsequent research fellowship at the Salk Institute and a clinical fellowship in developmental-behavioral pediatrics at Children’s Hospital of Philadelphia. He served on the faculty of that hospital from 1995 to 2002, focusing his clinical work on children with autism and intellectual disabilities, especially those resulting from genetic disorders. His research then focused on language and memory development in these patient populations. From 2002 to 2008, Wang worked at Pfizer, leading clinical trials in neurologic and psychiatric disorders. He subsequently led the clinical development of arbaclofen for autism and for fragile X syndrome at Seaside Therapeutics.

Wang joins the Simons Foundation from Autism Speaks, where he served as head of medical research for three years. He has held leadership positions in the American Academy of Pediatrics and the Society for Developmental and Behavioral Pediatrics, and he was one of seven founding members of the Sub-board of Developmental-Behavioral Pediatrics at the American Board of Pediatrics.

Clinical Operations, Biostatistical Analysis and Reporting, Clinical Research Associates

Karen Walton-Bowen joined Clinical Research Associates in 2014 to oversee clinical operations, biostatistical analysis and reporting, and the Arbaclofen program.

Walton-Bowen is an expert in clinical development across multiple therapeutic areas within the pharmaceutical and biotechnology industry, including gastrointestinal, neuroscience, respiratory, cardiovascular, lysosomal storage disorders, inflammation and pain control. Previously, Walton-Bowen worked at Seaside Therapeutics, L.L.C. as senior director of biometrics. There, she was responsible for the data-analytic aspects of the Arbaclofen programs, which aimed to treat autism and Fragile X Syndrome.

Walton-Bowen holds a B.Sc. in mathematics and computing and an M.Sc. in medical statistics from the University of London in the U.K. She also holds Chartered Statistician and Chartered Scientist status through the Royal Statistical Society.